Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema
By Elana Gotkine HealthDay Reporter
THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema (BCRL), according to a study published in the April issue of Rehabilitation Oncology.
Cheryl L. Brunelle, P.T., from Massachusetts General Hospital in Boston, and colleagues examined diagnostic agreement among commonly utilized diagnostic thresholds for BCRL among 60 patients measured using four methods: tape measure (every 4 cm [Q4] and National Lymphedema Network [NLN] methods) converted to volume, optoelectronic limb volumetry, and bioimpedance spectroscopy (BIS). Relative volume change (RVC) ≥10 percent, absolute volume difference ≥10 percent, and L-Dex scores >6.5 or >10 with and without preoperative baseline were compared as diagnostic thresholds.
Data were analyzed from 57 participants; 36.8 percent were diagnosed with BCRL (RVC ≥10 percent). The researchers found that when BCRL diagnosis included preoperative baseline, poor and insignificant diagnostic agreement was seen between RVC ≥10 percent and L-Dex increase ≥6.5 (Cohen's kappa, −0.083). Fair diagnostic agreement was seen between diagnosis made with versus without incorporation of preoperative baseline measurement (with preoperative baseline RVC and BIS: Cohen's kappa, 0.233; without preoperative baseline NLN, Q4, volumeter, or BIS without baseline: Cohen's kappa, 0.308); moderate agreement was seen for diagnosis via RVC versus volumeter (Cohen's kappa, 0.531). No diagnostic agreement was seen between L-Dex increase ≥6.5 from baseline and measures without preoperative baseline (NLN, Q4, and volumeter) for the 21 patients with BIS baseline.
"Our findings highlight the unacceptably low levels of agreement between different tests for recognizing this complication, and the urgent need to establish standardized diagnostic criteria," Brunelle said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Odds of Advanced Cancer, Breast Cancer Death Lower in Screen-Detected Disease
THURSDAY, June 5, 2025 -- For patients aged 40 years or older, screen-detected breast cancer is associated with lower odds of advanced cancer, mastectomy, and breast...
Nodal Irradiation Does Not Reduce Recurrence, Death for ypN0 Breast Cancer
THURSDAY, June 5, 2025 -- For patients with node-positive breast cancer who become pathologically tumor-free with negative axillary nodes (ypN0) after neoadjuvant chemotherapy...
ASCO: Vepdegestrant Ups Survival in ER+, HER2− Advanced Breast Cancer With ESR1 Mutations
MONDAY, June 2, 2025 -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.